Leo Pharma A/S
A/SActiveCVR 56759514Industriparken 55, 2750 BallerupManufacture of pharmaceutical preparations· NACE 2120Est. 1962 · 64 years old1,047 employees
Loading company…
Overview
Leo Pharma A/S is a Danish A/S based in Ballerup, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 1962, the company has 1,047 employees and reported revenue of DKK 11.5bn in its latest annual filing.
Revenue 2025
11.5B DKK
0% vs 2023
EBITDA margin
3.3 %
+109% vs 2023
Net profit 2025
2.5B DKK
+168% vs 2023
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
26.7 %
WeakAmong the 40% lowest rated companies in the industry
20202025
Liquidity ratioCurrent assets ÷ Short-term debt
1.0×
WeakAmong the 30% lowest rated companies in the industry
20202025
Return on assets (ROA)Net profit ÷ Total assets × 100
12.7 %
StrongAmong the 30% highest rated companies in the industry
20202025
EBITDA — year on year
DKK millionsKey figures
Annual report 2025| Revenue | 11.5B DKK | 0% |
| EBITDA | 0.4B DKK | +109% |
| Net profit | 2.5B DKK | +168% |
| Total assets | 19.5B DKK | -2% |
| Equity | 5.2B DKK | +16% |
| Employees | 1,047 | — |
Company information
Legal name
LEO PHARMA A/S
CVR number
56759514
Legal form
Aktieselskab
NACE code
Founded
10 February 1962 · 64 years
Share capital
DKK 383,582,682
Employees
1,047 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af formanden og en næstformand i forening, formanden i forening med et bestyrelsesmedlem, formanden i forening med den administrerende direktør, en næstformand i forening med den administrerende direktør, den administrerende direktør i forening med et bestyrelsesmedlem, to bestyrelsesmedlemmer i forening med en direktør, to direktører i forening, eller den samlede bestyrelse i forening.
Company purpose
Selskabets formål er at drive industrivirksomhed og handel.
(no translation available)
Address
Industriparken 55, 2750 Ballerup
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Leo Pharma A/S reported revenue of DKK 11.5bn, broadly in line with the year before. The figures on this page draw on 5 annual filings covering 2020 to 2025. The bottom line showed a net profit of DKK 2.5bn, and the EBITDA margin stood at 3.3%.
At the end of 2025, equity financed 26.7% of the balance sheet, and current assets covered short-term debt 1 times.
Financials
Revenue
DKK millionsEBITDA
DKK millionsIncome statement
DKK thousands| Item | 2025 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 11,497,000 | 11,497,000 | 12,935,000 | 9,606,000 | 8,284,000 |
| Staff expenses | — | -1,614,000 | -1,751,000 | -1,882,000 | -1,809,000 |
| EBITDA | 379,000 | -4,183,000 | -4,614,000 | -6,352,000 | -3,046,000 |
| Depreciation & amort. | — | -0 | -0 | -0 | -0 |
| EBIT | 379,000 | -4,183,000 | -4,614,000 | -6,352,000 | -3,046,000 |
| Net financials | 1,121,000 | 793,000 | 453,000 | 1,165,000 | 1,656,000 |
| Profit before tax | 1,500,000 | -3,390,000 | -4,161,000 | 5,188,000 | -1,390,000 |
| Tax | -973,000 | 250,000 | -13,000 | -308,000 | -459,000 |
| Net profit | 2,473,000 | -3,640,000 | -4,148,000 | 4,880,000 | -931,000 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | 19,452,000 | 19,939,000 | 29,743,000 | 28,148,000 | 25,317,000 |
| Equity | 5,184,000 | 4,488,000 | 1,942,000 | 5,619,000 | 7,017,000 |
| Long-term debt | 8,688,000 | 10,891,000 | 14,428,000 | 9,753,000 | 9,435,000 |
| Short-term debt | 5,456,000 | 4,444,000 | 12,987,000 | 12,503,000 | 8,560,000 |
| Total debt | 14,144,000 | 15,335,000 | 27,801,000 | 22,529,000 | 17,995,000 |
Financial ratios
5-year trendEBITDA margin
3.3 %
20202025
Equity ratio
26.7 %
WeakAmong the 40% lowest rated companies in the industry
20202025
Return on equity
47.7 %
Very strongAmong the 20% highest rated companies in the industry
20202025
Net profit margin
21.5 %
Very strongAmong the 20% highest rated companies in the industry
20202025
Asset turnover
0.59×
WeakAmong the 40% lowest rated companies in the industry
20202025
Debt / equity
2.75×
Very weakAmong the 20% lowest rated companies in the industry
20202025
Sector performance
24 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginStrong
Among the 30% highest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginAverage
Around the average of companies in the same industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery strong
Among the 20% highest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Very strong
Among the 20% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Strong
Among the 30% highest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very strong
Among the 20% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Average
Around the average of companies in the same industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioAverage
Around the average of companies in the same industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 30% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioWeak
Among the 30% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityStrong
Among the 30% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery weak
Among the 20% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery weak
Among the 20% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 40% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 40% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 20% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 20% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtStrong
Among the 40% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 40% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 40% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverWeak
Among the 40% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverStrong
Among the 40% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalStrong
Among the 40% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's equity.
One-year change in debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
TC Deputy | Deputy | 2026 |
PH Management | Management | 2022 |
KL Deputy | Deputy | 2026 |
CD Chief Executive Officer | Chief Executive Officer | 2022 |
CD Deputy | Deputy | 2026 |
HB Deputy | Deputy | 2026 |
Former (47)
Bv Deputy | Deputy | 1962 – 1990 |
GK Deputy | Deputy | 1998 – 2002 |
HN Chief Executive Officer | Chief Executive Officer | 1962 – 1994 |
KL Deputy | Deputy | 2022 – 2026 |
CT Chief Executive Officer | Chief Executive Officer | 2019 – 2021 |
LC Deputy | Deputy | 2022 – 2022 |
MD Deputy | Deputy | 2014 – 2016 |
LB | Deputy | 2019 – 2020 |
LO Management | Management | 2007 – 2015 |
PB Deputy | Deputy | 2025 – 2026 |
JV Deputy | Deputy | 2010 – 2014 |
JB Deputy | Deputy | 2002 – 2006 |
JR Deputy | Deputy | 1997 – 2002 |
AB Deputy | Deputy | 2010 – 2014 |
SI Deputy | Deputy | 2018 – 2022 |
JK Deputy | Deputy | 1998 – 1998 |
KA Deputy | Deputy | 2006 – 2007 |
JR Deputy | Deputy | 2016 – 2018 |
AK Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
IS Deputy | Deputy | 1962 – 1994 |
KB Deputy | Deputy | 2002 – 2003 |
ET Management | Management | 1999 – 2005 |
HA | Deputy | 1998 – 1998 |
AE Audit | Audit | 1962 – 1990 |
TC Deputy | Deputy | 2024 – 2026 |
EF Management | Management | 1962 – 1988 |
BP Deputy | Deputy | 2006 – 2008 |
SM Deputy | Deputy | 2023 – 2025 |
EL Chief Executive Officer | Chief Executive Officer | 2008 – 2007 |
LK Deputy | Deputy | 2014 – 2018 |
RR Deputy | Deputy | 2025 – 2026 |
JC Management | Management | 2006 – 2012 |
AS Deputy | Deputy | 1962 – 1998 |
AB Management | Management | 2012 – 2014 |
MR Deputy | Deputy | 1962 – 1994 |
GP Chief Executive Officer | Chief Executive Officer | 2008 – 2019 |
JH Management | Management | 1962 – 1994 |
TE Deputy | Deputy | 2022 – 2023 |
VO Management | Management | 1962 – 1992 |
MB Deputy | Deputy | 2010 – 2014 |
JB Management | Management | 1999 – 2010 |
IA Deputy | Deputy | 2018 – 2019 |
MV Deputy | Deputy | 2014 – 2014 |
PR Management | Management | 1962 – 2000 |
FF Deputy | Deputy | 2018 – 2021 |
AC Deputy | Deputy | 2014 – 2018 |
KM | Deputy | 2022 – 2025 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (13) | ||
HM Board of Directors | Board of Directors | 2026 |
PH Deputy Chairman | Deputy Chairman | 2026 |
FM Board of Directors | Board of Directors | 2022 |
LE Board of Directors | Board of Directors | 2022 |
SM Board of Directors | Board of Directors | 2022 |
PO Deputy Chairman | Deputy Chairman | 2023 |
JB Chairman | Chairman | 2021 |
TC Board of Directors | Board of Directors | 2026 |
MP Board of Directors | Board of Directors | 2025 |
KF Board of Directors | Board of Directors | 2026 |
RR Board of Directors | Board of Directors | 2024 |
AA Board of Directors | Board of Directors | 2025 |
AC Board of Directors | Board of Directors | 2026 |
Former (45)
HN Chairman | Chairman | 1962 – 2000 |
JH Board of Directors | Board of Directors | 2016 – 2021 |
OB Chairman | Chairman | 2019 – 2021 |
| Chairman | 1962 – 1988 | |
VJ Board of Directors | Board of Directors | 1962 – 1996 |
NS Board of Directors | Board of Directors | 1962 – 2006 |
LO Board of Directors | Board of Directors | 2008 – 2011 |
JB Board of Directors | Board of Directors | 2007 – 2010 |
JR Board of Directors | Board of Directors | 1997 – 1998 |
LH Board of Directors | Board of Directors | 2010 – 2018 |
JM Deputy Chairman | Deputy Chairman | 2022 – 2023 |
JK Board of Directors | Board of Directors | 2022 – 2026 |
LG Board of Directors | Board of Directors | 2021 – 2026 |
GM Board of Directors | Board of Directors | 1999 – 2014 |
KA Board of Directors | Board of Directors | 2022 – 2024 |
JR Board of Directors | Board of Directors | 2010 – 2014 |
AE Board of Directors | Board of Directors | 1962 – 1990 |
PJ Board of Directors | Board of Directors | 1962 – 2006 |
HA Board of Directors | Board of Directors | 1998 – 2002 |
JM Board of Directors | Board of Directors | 2019 – 2022 |
HC Board of Directors | Board of Directors | 1962 – 1997 |
CP Board of Directors | Board of Directors | 2017 – 2021 |
AC Board of Directors | Board of Directors | 1997 – 2000 |
EF Board of Directors | Board of Directors | 1962 – 1996 |
PH Board of Directors | Board of Directors | 2011 – 2018 |
EL Chairman | Chairman | 2008 – 2008 |
AV Board of Directors | Board of Directors | 1962 – 1994 |
BJ Board of Directors | Board of Directors | 2002 – 2006 |
JC Board of Directors | Board of Directors | 2008 – 2011 |
GP Board of Directors | Board of Directors | 2007 – 2011 |
CL Board of Directors | Board of Directors | 1962 – 1994 |
IS Board of Directors | Board of Directors | 2014 – 2018 |
VO Board of Directors | Board of Directors | 1962 – 1999 |
JP Chairman | Chairman | 2016 – 2019 |
JG Board of Directors | Board of Directors | 2017 – 2024 |
JB Board of Directors | Board of Directors | 2000 – 2017 |
AE Deputy Chairman | Deputy Chairman | 2021 – 2022 |
PR Chairman | Chairman | 2008 – 2016 |
JM Board of Directors | Board of Directors | 2006 – 2007 |
PH Board of Directors | Board of Directors | 2000 – 2014 |
JR Board of Directors | Board of Directors | 2014 – 2019 |
NS Board of Directors | Board of Directors | 2008 – 2011 |
PO Deputy Chairman | Deputy Chairman | 2016 – 2018 |
JW Board of Directors | Board of Directors | 2021 – 2024 |
HB Board of Directors | Board of Directors | 2024 – 2026 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 66.67–89.99% | 90–99.99% | 2021 | |
Cidron Savanna 4 SARL | Company | 15–19.99% | 0% | 2023 |
| Company | 100% | 100% | 1993 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Leo Fondet
Leo Pharma A/S Board network connections
Board members of Leo Pharma A/S also hold positions in 281 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Green | Board of Directors | 130 companiesMany roles |
| Marianne Viskum Olesen | Deputy | 14 companiesMany roles |
| Cristina Patricia Lage | Board of Directors | 12 companiesMany roles |
| Kasper Fangel | Board of Directors | 12 companiesMany roles |
| Patrik Olof Dahlén | Deputy Chairman | 9 companiesMany roles |
| Jonas Wilhelm Agnblad | Board of Directors | 9 companiesMany roles |
| Gitte Pugholm Aabo | Chief Executive Officer | 8 companiesMany roles |
| Jukka Pekka Pertola | Chairman | 8 companiesMany roles |
| Anders Bendsen Spohr | Management | 7 companiesMany roles |
| Jesper Mailind | Deputy Chairman | 7 companiesMany roles |
| Thorsten Erik Ramsing | Deputy | 6 companiesMany roles |
| Jesper Brandgaard | Chairman | 6 companiesMany roles |
| Lars Olsen | Management | 5 companies |
| Peter Helt Jacobsen Haahr | Deputy Chairman | 5 companies |
| Peder Holk Nielsen | Board of Directors | 5 companies |
| Erik Torngaard Hansen | Management | 4 companies |
| Henriette Mersebach | Board of Directors | 4 companies |
| Lotte Hjortshøj | Board of Directors | 4 companies |
| Philip Harald Eickhoff | Management | 3 companies |
| Jesper Høiland | Board of Directors | 3 companies |
| Klaus Legau | Deputy | 2 companies |
| Louisa Channouf Jacobsen | Deputy | 2 companies |
| Anders Kronborg | Chief Executive Officer | 2 companies |
| John Carsten Mehlbye | Management | 2 companies |
| Kreesten Meldgaard Madsen | Deputy | 2 companies |
| Ingelise Saunders | Board of Directors | 2 companies |
| Per Håkon Schmidt | Board of Directors | 2 companies |
| Morten Drewes Pedersen | Deputy | 1 company |
| Poul Bo Kilund | Deputy | 1 company |
| Jens Vallentin Holm | Deputy | 1 company |
| Thomas Christian Facius | Deputy | 1 company |
| Allan Carsten Dahl | Deputy | 1 company |
| Henrik Bo Andersson | Deputy | 1 company |
Frequently asked questions
What is the CVR number of Leo Pharma A/S?
Leo Pharma A/S is registered with CVR / Virk under CVR 56759514.
What is the revenue of Leo Pharma A/S?
Leo Pharma A/S reported revenue of DKK 11.5bn in 2025.
How many employees does Leo Pharma A/S have?
Leo Pharma A/S employs 1047 people as of the latest annual report.
Who is the CEO of Leo Pharma A/S?
Christophe Dominique Luc Charles Bourdon is the CEO of Leo Pharma A/S, in role since 2022.
Who is the chairman of Leo Pharma A/S?
Jesper Brandgaard chairs the board of Leo Pharma A/S, in role since 2021.
Where is Leo Pharma A/S headquartered?
Leo Pharma A/S's registered address is Industriparken 55.